Literature DB >> 28798070

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

Josephine M Vos1,2, Nickolas Tsakmaklis2, Christopher J Patterson2, Kirsten Meid2, Jorge J Castillo2,3, Philip Brodsky2, Tomas Ganz4, Steven T Pals5, Marie José Kersten6, Lian Xu2, Guang Yang2,3, Steven P Treon2,3, Zachary R Hunter2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28798070      PMCID： PMC5664407          DOI： 10.3324/haematol.2017.172627

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Willem Kraan; Marie José Kersten; Steven P Treon; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

2.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

3.  Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.

Authors:  Claudio Tripodo; Giorgia Gri; Pier Paolo Piccaluga; Barbara Frossi; Carla Guarnotta; Silvia Piconese; Giovanni Franco; Valeria Vetri; Carlo Ennio Pucillo; Ada Maria Florena; Mario Paolo Colombo; Stefano Aldo Pileri
Journal:  Am J Pathol       Date:  2010-07-01       Impact factor: 4.307

4.  Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Authors:  Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

5.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors:  Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

6.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

7.  Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

Authors:  Lian Xu; Zachary R Hunter; Nicholas Tsakmaklis; Yang Cao; Guang Yang; Jie Chen; Xia Liu; Sandra Kanan; Jorge J Castillo; Yu-Tzu Tai; James L Zehnder; Jennifer R Brown; Ruben D Carrasco; Ranjana Advani; Jean M Sabile; Kimon Argyropoulos; M Lia Palomba; Enrica Morra; Alessandra Trojani; Antonino Greco; Alessandra Tedeschi; Marzia Varettoni; Luca Arcaini; Nikhil M Munshi; Kenneth C Anderson; Steven P Treon
Journal:  Br J Haematol       Date:  2015-12-13       Impact factor: 6.998

8.  Immunoassay for human serum hepcidin.

Authors:  Tomas Ganz; Gordana Olbina; Domenico Girelli; Elizabeta Nemeth; Mark Westerman
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

9.  CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

Authors:  Allen W Ho; Evdoxia Hatjiharissi; Bryan T Ciccarelli; Andrew R Branagan; Zachary R Hunter; Xavier Leleu; Olivier Tournilhac; Lian Xu; Kelly O'Connor; Robert J Manning; Daniel Ditzel Santos; Mariana Chemaly; Christopher J Patterson; Jacob D Soumerai; Nikhil C Munshi; Julie A McEarchern; Che-Leung Law; Iqbal S Grewal; Steven P Treon
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Authors:  Carsten U Niemann; Sarah E M Herman; Irina Maric; Julio Gomez-Rodriguez; Angelique Biancotto; Betty Y Chang; Sabrina Martyr; Maryalice Stetler-Stevenson; Constance M Yuan; Katherine R Calvo; Raul C Braylan; Janet Valdez; Yuh Shan Lee; Deanna H Wong; Jade Jones; Clare Sun; Gerald E Marti; Mohammed Z H Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-12-09       Impact factor: 12.531
View more
  9 in total

1.  Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

Authors:  Tomasz Sewastianik; Maria Luisa Guerrera; Keith Adler; Peter S Dennis; Kyle Wright; Vignesh Shanmugam; Ying Huang; Helen Tanton; Meng Jiang; Amanda Kofides; Maria G Demos; Audrey Dalgarno; Neil A Patel; Anwesha Nag; Geraldine S Pinkus; Guang Yang; Zachary R Hunter; Petr Jarolim; Nikhil C Munshi; Steven P Treon; Ruben D Carrasco
Journal:  Blood Adv       Date:  2019-11-12

2.  Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Joshua N Gustine; Kirsten Meid; Toni Dubeau; Patricia Severns; Steven P Treon
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

3.  Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.

Authors:  David F Moreno; Arturo Pereira; Natalia Tovar; María Teresa Cibeira; Laura Magnano; María Rozman; Mónica López-Guerra; Dolors Colomer; Beatriz Martín-Antonio; Raquel Jiménez-Segura; Ignacio Isola; Luis Gerardo Rodríguez-Lobato; Aina Oliver-Caldés; Mari Pau Mena; Laura Rosiñol; Joan Bladé; Carlos Fernández de Larrea
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

4.  Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.

Authors:  Jorge J Castillo; Shayna R Sarosiek; Joshua N Gustine; Catherine A Flynn; Carly R Leventoff; Timothy P White; Kirsten Meid; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Zachary R Hunter; Christopher J Patterson; Andrew R Branagan; Steven P Treon
Journal:  Blood Adv       Date:  2022-02-08

5.  CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression.

Authors:  Katia Beider; Valeria Voevoda-Dimenshtein; Ali Zoabi; Evgenia Rosenberg; Hila Magen; Olga Ostrovsky; Avichai Shimoni; Lola Weiss; Michal Abraham; Amnon Peled; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2022-10-10       Impact factor: 23.168

Review 6.  Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

7.  Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.

Authors:  Steven P Treon; Kirsten Meid; Joshua Gustine; Guang Yang; Lian Xu; Xia Liu; Christopher J Patterson; Zachary R Hunter; Andrew R Branagan; Jacob P Laubach; Irene M Ghobrial; M Lia Palomba; Ranjana Advani; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544

8.  Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.

Authors:  Zemene Demelash Kifle
Journal:  Metabol Open       Date:  2021-07-29

9.  The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.

Authors:  Steven P Treon; Jorge J Castillo; Alan P Skarbnik; Jacob D Soumerai; Irene M Ghobrial; Maria Luisa Guerrera; Kirsten Meid; Guang Yang
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.